Brought to you by 
OncoMed closes $154mm Series B round; later adds on $15mm
30 Oct 2017
Executive Summary
OncoMed Pharmaceuticals (anticancer stem cell antibodies) has raised $93mm through the second and final closing of its Series B round, bringing the total amount to $154mm. New investor Nomura Phase4 Ventures participated, along with returning buyers US Venture Partners, Latterell Venture Partners, the Vertical Group, Morgenthaler Ventures, Adams Street Partners, De Novo Ventures, Bay Partners, and development partner GlaxoSmithKline. Nomura Phase4's managing director will join OncoMed's board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
OncoMed closes $154mm Series B round; later adds on $15mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice